本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Edgewise Therapeutics, Inc.

29.06
-0.9900-3.29%
盤前28.90-0.1600-0.55%04:12 EDT
成交量:100.43萬
成交額:2,949.12萬
市值:31.17億
市盈率:-17.83
高:30.44
開:30.10
低:28.87
收:30.05
52周最高:31.82
52周最低:10.60
股本:1.07億
流通股本:6,084.98萬
量比:1.37
換手率:1.65%
股息:- -
股息率:- -
每股收益(TTM):-1.6302
每股收益(LYR):-1.6302
淨資產收益率:-34.19%
總資產收益率:-23.02%
市淨率:5.97
市盈率(LYR):-17.83

資料載入中...

公司資料

公司名字:
Edgewise Therapeutics, Inc.
交易所:
NASDAQ
成立時間:
2017
員工人數:
146
公司地址:
1715 38th Street,Boulder,Colorado,United States
郵編:
80301
電話:
傳真:
- -
簡介:
Edgewise Therapeutics, Inc.於2017年5月在特拉華州註冊成立。該公司是一家以科學為驅動的生物技術公司,專註於開發針對嚴重肌肉疾病的療法,最初目標是罕見神經肌肉和心臟疾病。其主要候選藥物sevasemten是一種口服小分子抑製劑,正處於治療杜氏肌營養不良和貝克爾肌營養不良的後期臨床開發階段。

董事

名稱
職位
Kevin Koch
President, Chief Executive Officer and Director
Alan Russell
Chief Scientific Officer and Director
Peter Thompson
Director and Chairperson
Arlene M. Morris
Director
Badreddin Edris
Director
Christopher Martin
Director
Jonathan Fox
Director
Jonathan Root
Director
Laura Brege
Director

股東

名稱
職位
Kevin Koch
President, Chief Executive Officer and Director
Robert Blaustein
Chief Operating Officer
Michael Nofi
Chief Financial Officer
Alan Russell
Chief Scientific Officer and Director
Behrad Derakhshan
Chief Business Officer
Joanne M. Donovan
Chief Medical Officer
John Moore
General Counsel